Detection of monoclonal antibody-defined colorectal carcinoma antigen by solid-phase binding inhibition radioimmunoassay.
We have established a solid-phase binding inhibition radioimmunoassay for the detection of colorectal carcinoma-specific antigens in tissue culture supernatants of human colorectal carcinoma cell lines and in serum and urine of colorectal carcinoma patients. Using the [3H]glucosamine-labeled cell membrane glycolipid antigen and colorectal carcinoma-specific monoclonal antibodies in this assay, we have been able to detect several human colorectal carcinoma membrane-specific antigens that are released from the cell membrane into tissue culture supernatants, and an antigen detected by antibodies 1116-NS-19-9 and 1116-NS-52a that is found only in the serum and urine of cancer patients.
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology / Q000652:urine; D002460:Cell Line; D003110:Colonic Neoplasms / Q000276:immunology* / Q000652:urine; D005732:Gangliosides / Q000032:analysis* / Q000276:immunology / Q000652:urine; D006801:Humans; D006825:Hybridomas; D011863:Radioimmunoassay; D012004:Rectal Neoplasms / Q000276:immunology* / Q000652:urine
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D005732:Gangliosides; C028885:colon carcinoma monosialoganglioside antigen